Cancer
|

Peptide warehouse for the development of personalized immunotherapies to eliminate residual leukemic progenitor cells in acute myeloid leukemia (AML

Institution: Abteilung für Peptid-basierte Immuntherapie und Klinische Kooperationseinheit (KKE) Translationale Immunologie, Universität und Universitätsklinikum Tübingen
Applicant: Prof. Dr. Juliane Walz
Funding line:
Translational Research
Image

Immunotherapies are novel and promising treatment options for cancer patients. Many of these immunotherapies aim to activate the so-called T cells as highly effective defense cells of the immune system. T cells recognize foreign surface markers on tumor cells and can then destroy them.
In acute myeloid leukemia, the most common acute blood cancer in adults, leukemic progenitor cells often remain after therapy, leading to a relapse of the disease. Here, T cell-based immunotherapies could help as a new treatment option to specifically target these remaining progenitor cells.
In this project, a vaccine will be produced and clinically evaluated to direct the immune system specifically against these leukemia progenitor cells in order to substantially improve the cure rate of patients.

Here you can find further information.

Image